Phylloquinone (Vitamin K1) : Physiology, Evidence, and Clinical Translation

Phylloquinone: The Hepatic Coagulation Vitamin and the Circulating Precursor for Extrahepatic Menaquinone Synthesis

Phylloquinone, designated vitamin K1, is a fat-soluble vitamin composed of a 2-methyl-1,4-naphthoquinone ring conjugated to a monounsaturated phytyl side chain, a 20-carbon isoprenoid tail that distinguishes it structurally from the bacterial menaquinones. Phylloquinone is synthesized exclusively by plants, algae, and cyanobacteria, where it functions as the single-electron carrier A1 in photosystem I, an indispensable component of the photosynthetic electron transport chain. Humans cannot synthesize the naphthoquinone ring and must obtain phylloquinone from the diet, primarily from green leafy vegetables, or from the tissue-specific conversion of phylloquinone to menaquinone-4 (MK-4), a process that occurs in the brain, pancreas, testis, kidney, salivary glands, and arterial wall. For over half a century, the clinical understanding of phylloquinone was confined to its hepatic function: it is the essential cofactor for the gamma-glutamyl carboxylase that activates the vitamin K-dependent coagulation factors, and it is the antidote to warfarin. That understanding, while correct, is incomplete. Phylloquinone is not merely a coagulation vitamin. It is the circulating precursor pool from which a significant fraction of the body's extrahepatic menaquinone-4 is synthesized, and it is the primary substrate that sustains the carboxylation of the hepatic Gla proteins under normal physiological conditions. This monograph analyzes phylloquinone's systemic biology, maps the clinical evidence by context, and constructs a dosing framework that spans the emergency reversal of life-threatening hemorrhage to the chronic maintenance of extrahepatic Gla protein function, while distinguishing clearly between the hepatic role of phylloquinone and the extrahepatic role of the menaquinones.

---

Part 1. The Structural and Metabolic Identity of Phylloquinone

Phylloquinone is a 2-methyl-1,4-naphthoquinone with a phytyl side chain at the 3-position. The phytyl chain is a 20-carbon, partially unsaturated isoprenoid with a single double bond, a structural feature that renders phylloquinone more polar and less lipophilic than the long-chain menaquinones with their multiple double bonds. This single structural difference, the saturation and length of the side chain, is the primary determinant of the pharmacokinetic and tissue distribution profile that distinguishes phylloquinone from the menaquinones. The naphthoquinone ring is identical in all forms of vitamin K and is the redox-active core that cycles between the hydroquinone, quinone, and epoxide forms during the gamma-carboxylation reaction.

1A. Dietary Sources and the Chloroplast Connection

Phylloquinone is synthesized in the chloroplast of green plants, where it is tightly bound to the photosystem I reaction center and functions as the phylloquinone electron acceptor A1. It is therefore present in all green leafy tissues, with the highest concentrations found in spinach, kale, collard greens, broccoli, and Brussels sprouts. The vitamin K content of these foods is directly proportional to their chlorophyll content, a relationship that provides a simple dietary heuristic: the darker the green of the leaf, the higher the phylloquinone concentration. Certain plant oils, particularly soybean oil, canola oil, and olive oil, contain lower but significant amounts of phylloquinone and contribute substantially to total intake in Western diets because of their ubiquitous use in processed foods.

The absorption of phylloquinone from raw leafy vegetables is relatively inefficient, approximately 10 to 20 percent of the ingested dose, because the vitamin is tightly embedded in the thylakoid membranes of the chloroplast and is not fully released by mastication and gastric digestion. The co-consumption of dietary fat, which stimulates the secretion of bile salts and pancreatic lipase, substantially enhances the absorption of phylloquinone by facilitating its release from the plant matrix and its incorporation into mixed micelles. A spinach salad consumed with an oil-based dressing delivers several times more bioavailable phylloquinone than the same spinach consumed without fat. This is a clinically significant point: the dietary assessment of vitamin K intake must account not only for the phylloquinone content of the food but also for the context of its consumption. The efficiency of absorption from plant oils, where the vitamin is already in free solution, is substantially higher than from intact leafy vegetables.

1B. Absorption, Chylomicron Transport, and Hepatic Sequestration

Phylloquinone is absorbed from the jejunum by a process that is identical to that of the other fat-soluble vitamins and the menaquinones. It requires the formation of mixed micelles with bile salts and fatty acids, uptake into the enterocyte by facilitated diffusion and, at low concentrations, by the scavenger receptor class B type I (SR-BI) and the Niemann-Pick C1-like 1 (NPC1L1) transporter, incorporation into chylomicrons by the action of microsomal triglyceride transfer protein, and secretion into the intestinal lymph. The chylomicrons deliver phylloquinone to the systemic circulation via the thoracic duct, and the chylomicron remnants, which retain the majority of the phylloquinone, are taken up by the liver through the low-density lipoprotein receptor-related protein (LRP) and the heparan sulfate proteoglycans on the hepatocyte surface.

This is the critical branch point in the metabolic fate of phylloquinone. The liver extracts approximately 50 to 90 percent of the dietary phylloquinone on first pass, and this hepatic pool is the substrate for the gamma-carboxylation of the coagulation factors. The fraction of dietary phylloquinone that escapes hepatic uptake and circulates to extrahepatic tissues is small, and the plasma concentration of phylloquinone is correspondingly low, typically in the range of 0.5 to 2.0 nanograms per milliliter in a replete individual. The phylloquinone that escapes the hepatic first pass is distributed to the peripheral tissues on the triglyceride-rich lipoproteins, primarily very-low-density lipoproteins (VLDL), which are secreted by the liver and undergo lipolysis to low-density lipoproteins (LDL). The plasma concentration of phylloquinone is therefore tightly correlated with the plasma triglyceride concentration.

The plasma half-life of phylloquinone is approximately 1 to 2 hours. The molecule is rapidly cleared by the liver and catabolized by the cytochrome P450 system, primarily CYP4F2, which hydroxylates the phytyl side chain, initiating a process of beta-oxidation that shortens the side chain to 5 to 7 carbon atoms and generates carboxylic acid metabolites that are excreted in the bile and urine. The urinary excretion of these metabolites, particularly the 5-carbon and 7-carbon side chain aglycones, provides a measure of total body vitamin K turnover and has been used as a biomarker of vitamin K status. The total body pool of phylloquinone is small, approximately 50 to 100 micrograms, and the turnover is rapid. The liver stores are sufficient to maintain coagulation factor synthesis for only a few days in the absence of dietary intake.

This pharmacokinetic profile explains why the coagulation system is the first to fail in severe vitamin K deficiency and why the extrahepatic Gla proteins, which require a sustained, long-half-life vitamin K form for their complete carboxylation, are better served by the menaquinones, particularly MK-7, than by phylloquinone. The rapid clearance and short half-life are the reasons that phylloquinone is a poor extrahepatic vitamin K source compared to the long-chain menaquinones, which have half-lives measured in days.

1C. The UBIAD1-Mediated Conversion of Phylloquinone to Menaquinone-4

The human body possesses an unexpected metabolic capacity: it can cleave the phytyl side chain from phylloquinone and replace it with a geranylgeranyl side chain to synthesize menaquinone-4 (MK-4). This conversion does not occur in the liver. It occurs in specific extrahepatic tissues, including the brain, the pancreas, the testis, the kidney, the arterial wall, and the salivary glands, and it is catalyzed by the enzyme UBIAD1 (UbiA prenyltransferase domain-containing protein 1). UBIAD1 is located in the endoplasmic reticulum and Golgi apparatus, and it transfers a geranylgeranyl group from geranylgeranyl pyrophosphate to menadione, the naphthoquinone ring that is generated from phylloquinone by the cleavage of the phytyl side chain. The menadione intermediate is then converted to MK-4.

This conversion pathway is the mechanism by which dietary phylloquinone contributes to the extrahepatic pool of vitamin K2. The tissues that express UBIAD1 can take up circulating phylloquinone, cleave its side chain, and synthesize MK-4 locally, where it supports the carboxylation of the tissue-specific Gla proteins, including Gas6 in the brain and matrix Gla protein in the arterial wall. The efficiency of this conversion is not fully understood, and the extent to which dietary phylloquinone sustains tissue MK-4 levels in humans is a subject of ongoing investigation. The conversion is likely sufficient to prevent the most severe consequences of extrahepatic vitamin K deficiency but may not be sufficient to achieve the optimal carboxylation of MGP and osteocalcin, which requires the sustained supply of the long-chain menaquinones.

The physiological significance of this conversion is a matter of active investigation. One hypothesis is that phylloquinone serves as a circulating pro-vitamin that is converted to the tissue-active menaquinone at sites where MK-4 has specific functions, such as the brain, where MK-4 is the predominant vitamin K form and where it supports Gas6-mediated oligodendrocyte survival and the synthesis of sulfatides, the myelin lipids. An alternative hypothesis is that the UBIAD1-mediated conversion is a clearance mechanism for phylloquinone, removing the phytyl side chain and generating a menaquinone that is more stable in the tissue membranes. Regardless of the evolutionary rationale, the conversion establishes that phylloquinone is a source of MK-4 for the extrahepatic tissues, and that the dietary intake of phylloquinone contributes to the extrahepatic Gla protein carboxylation indirectly through its conversion to MK-4. This pathway provides a mechanistic link between phylloquinone intake and the non-coagulation functions of vitamin K, and it suggests that a dietary deficiency of phylloquinone may have consequences that extend beyond the prolongation of the prothrombin time.

1D. The Vitamin K Cycle in the Hepatocyte

The hepatic utilization of phylloquinone follows the canonical vitamin K cycle. Phylloquinone is reduced to its hydroquinone form (KH2) by the enzyme vitamin K epoxide reductase (VKORC1) and, to a lesser extent, by NAD(P)H-dependent quinone reductases. The hydroquinone serves as the cofactor for the gamma-glutamyl carboxylase, which converts glutamic acid residues to gamma-carboxyglutamic acid (Gla) residues in the nascent coagulation factors. During this reaction, KH2 is oxidized to vitamin K 2,3-epoxide, which is then reduced back to phylloquinone by VKORC1, completing the cycle. The anticoagulant warfarin inhibits VKORC1, depleting the hepatic pool of reduced phylloquinone and preventing the carboxylation of the vitamin K-dependent clotting factors.

The liver is preferentially protected against warfarin-induced vitamin K deficiency because it has a high concentration of phylloquinone, a high activity of VKORC1, and an alternative reduction pathway through the quinone reductases that is not inhibited by warfarin. The extrahepatic tissues, which have a lower concentration of vitamin K and a lower activity of the alternative reductases, are more vulnerable to the effects of warfarin, a difference that explains the accelerated arterial calcification and the increased fracture risk observed in patients on long-term warfarin therapy. This differential sensitivity between hepatic and extrahepatic tissues is the pharmacological basis for the clinical observation that the menaquinones, which preferentially supply the extrahepatic tissues, are the vitamin K forms most relevant to the prevention of warfarin-associated vascular and skeletal complications.

---

Part 2. The Hepatic and Extrahepatic Biology of Phylloquinone

Phylloquinone's biology is defined by its dual role: it is the primary substrate for the hepatic coagulation system, and it is the circulating precursor for tissue-specific MK-4 synthesis.

2A. The Coagulation System: The Canonical Function

The liver synthesizes the vitamin K-dependent coagulation factors: prothrombin (Factor II), Factor VII, Factor IX, and Factor X, as well as the anticoagulant proteins C, S, and Z. The Gla domains of these proteins, which contain 9 to 12 Gla residues, are located at the amino terminus. Upon calcium binding, the Gla domain undergoes a conformational change that enables the protein to bind to the phospholipid surface of activated platelets and endothelial cells, a localization that is essential for the assembly of the tenase and prothrombinase complexes that amplify the coagulation cascade. Phylloquinone, by maintaining the hepatic pool of reduced vitamin K, ensures that the coagulation factors are fully carboxylated and functionally competent.

The clinical measure of hepatic vitamin K status is the prothrombin time, expressed as the international normalized ratio (INR). An elevated INR indicates that the carboxylation of the hepatic coagulation factors is impaired, and this is the most sensitive clinical sign of a functionally significant vitamin K deficiency. The liver is so efficient at extracting and retaining phylloquinone that the INR remains normal until the hepatic phylloquinone stores are profoundly depleted, a state that occurs only after prolonged dietary deficiency, fat malabsorption, or warfarin therapy. The plasma concentration of PIVKA-II (protein induced by vitamin K absence or antagonism-II), the undercarboxylated form of prothrombin, rises before the INR becomes abnormal and is the most sensitive biomarker of hepatic vitamin K insufficiency.

2B. The Extrahepatic Gla Proteins and the Phylloquinone-Menaquinone Divide

The recognition that the vitamin K-dependent carboxylation system is not confined to the liver has expanded the clinical scope of phylloquinone. Osteocalcin in bone, matrix Gla protein (MGP) in the arterial wall, and Gas6 in the central nervous system and immune system are all synthesized in their undercarboxylated forms and require vitamin K for their activation. The liver, with its preferential extraction of phylloquinone from the portal circulation, is more efficient at carboxylating its proteins than are the peripheral tissues. The consequence is that the dietary intake of phylloquinone required to fully carboxylate the hepatic clotting factors is lower than the intake required to fully carboxylate osteocalcin and MGP. A state of subclinical vitamin K insufficiency, characterized by a normal INR but elevated plasma levels of undercarboxylated osteocalcin (ucOC) and undercarboxylated MGP (dp-ucMGP, the dephosphorylated, uncarboxylated form), is prevalent in populations with a low intake of both phylloquinone and menaquinones.

The osteoblast synthesizes osteocalcin, the most abundant non-collagenous protein of the bone matrix, which requires vitamin K-dependent carboxylation for its structural function. Phylloquinone is present in bone, albeit at lower concentrations than the menaquinones, and it can support the carboxylation of osteocalcin. Epidemiological studies have consistently found that low dietary phylloquinone intake is associated with a lower bone mineral density and an increased risk of hip fracture in older adults. The Framingham Heart Study found that individuals in the lowest quartile of phylloquinone intake had a 65 percent higher risk of hip fracture compared to those in the highest quartile. The Nurses' Health Study found a 30 percent reduction in hip fracture risk in women in the highest quintile of phylloquinone intake, though the association was attenuated after adjustment for other dietary factors.

The interventional trials of phylloquinone supplementation for bone health, however, have been less consistent than those of the menaquinones. A 2006 trial of phylloquinone at 500 micrograms per day for 3 years in postmenopausal women found no significant effect on bone mineral density at the lumbar spine or femoral neck, though a subsequent analysis of the same trial found a modest protective effect on bone mineral density at the femoral neck in a subgroup of women with low baseline vitamin K status. A 2009 systematic review and meta-analysis of five randomized trials of phylloquinone supplementation for bone mineral density found no significant effect at the lumbar spine or femoral neck. The interpretation of these data is that phylloquinone, at nutritional and moderate supplemental doses, can support the carboxylation of osteocalcin in the bone, but its short half-life and its preferential hepatic sequestration limit its capacity to fully activate the extrahepatic Gla proteins, a task that is better accomplished by the long-chain menaquinones, particularly MK-7.

The question of whether phylloquinone supplementation at nutritional doses can fully carboxylate the extrahepatic Gla proteins, or whether the menaquinones are required for this purpose, has been addressed in several clinical trials. Phylloquinone supplementation at doses of 500 to 1,000 micrograms per day reduces plasma ucOC, indicating that the bone osteoblasts can use phylloquinone for the carboxylation of osteocalcin when the plasma concentration is elevated to the supraphysiological range. The effect of phylloquinone on dp-ucMGP, the marker of arterial vitamin K status, is less pronounced than that of MK-7 at equivalent or lower doses. A 2009 trial comparing phylloquinone (1,000 micrograms per day) with MK-7 (360 micrograms per day) found that both reduced dp-ucMGP, but MK-7 produced a significantly greater and more sustained reduction. The explanation is pharmacokinetic. Phylloquinone, with its short half-life, is cleared from the plasma before it can be taken up by the vascular smooth muscle cells and used for the continuous carboxylation of MGP. MK-7, with its 2- to 3-day half-life, maintains a sustained plasma concentration that supports the ongoing carboxylation of MGP throughout the dosing interval.

The epidemiological data on phylloquinone and cardiovascular disease are consistent with this pharmacokinetic interpretation. The Rotterdam Study, which found a strong inverse association between dietary menaquinone intake and coronary heart disease mortality, found no such association for phylloquinone. The Multi-Ethnic Study of Atherosclerosis (MESA) found no association between dietary phylloquinone intake and coronary artery calcium progression. The interventional trials of phylloquinone for arterial stiffness or coronary calcification are sparse and have been negative. A 2009 trial of 500 micrograms per day of phylloquinone for 3 years in older adults with pre-existing coronary artery calcification found no effect on the rate of calcification progression.

The interpretation is that phylloquinone, with its short half-life and its preferential hepatic extraction, is not the vitamin K form that protects the arterial wall. The arterial protection is mediated by the menaquinones, and the clinical focus for the prevention of vascular calcification should be on the dietary intake of menaquinones from fermented foods and on the supplementation of MK-7, not on the escalation of phylloquinone intake. Phylloquinone should not be recommended as a monotherapy for the prevention or treatment of osteoporosis or vascular calcification.

2C. The UBIAD1 Tissue Network: Phylloquinone as the Circulating MK-4 Precursor

The tissues that express UBIAD1, the brain, the pancreas, the testis, the kidney, and the arterial wall, constitute a network of MK-4 synthesis that is dependent on circulating phylloquinone as its substrate. In the brain, MK-4 is the most abundant menaquinone, and its concentration exceeds that of phylloquinone by several-fold. The brain expresses UBIAD1 and can synthesize MK-4 from phylloquinone that has crossed the blood-brain barrier. This locally synthesized MK-4 supports the carboxylation of Gas6, which promotes the survival of oligodendrocytes, the cells that synthesize the myelin sheath, and enhances the phagocytic clearance of myelin debris and apoptotic cells by microglia. Gas6-TAM signaling is essential for the maintenance of white matter integrity and for the resolution of neuroinflammation.

In the pancreas, MK-4 is concentrated in the beta cells, where it may influence insulin secretion through a mechanism that is independent of the osteocalcin endocrine axis. In the testis, MK-4 is synthesized by the Leydig and Sertoli cells, where it supports testosterone synthesis and spermatogenesis. A 2011 study in male rats found that MK-4 supplementation increased testicular and plasma testosterone levels. A 2017 case series of 12 men with infertility and low serum MK-4 levels reported an improvement in sperm count and motility after 3 months of MK-4 supplementation at 45 mg per day, though no randomized controlled trial has been conducted.

The clinical implication of this conversion pathway is that dietary phylloquinone is not merely a hepatic coagulation vitamin. It is the systemic substrate for a network of tissue-specific MK-4 synthesis that supports the unique Gla protein functions of each of these organs. A deficiency of dietary phylloquinone is therefore not only a risk factor for coagulopathy but also a potential contributor to the dysfunction of the brain, the pancreas, and the reproductive system, a possibility that is supported by the tissue biology but has not been directly tested in human clinical trials. The UBIAD1 pathway provides a mechanistic link between phylloquinone intake and the non-coagulation functions of vitamin K, and it suggests that the optimal vitamin K status for the human organism requires the adequacy of both phylloquinone, for the liver and for the circulating precursor pool, and the menaquinones, for the extrahepatic tissues that cannot be adequately supplied by phylloquinone alone.

---

Part 3. The Clinical Taxonomy of Phylloquinone Deficiency

Phylloquinone deficiency is defined by an elevated prothrombin time and a prolonged INR, the clinical hallmarks of impaired hepatic coagulation factor synthesis. The deficiency can also be assessed by the measurement of the plasma phylloquinone concentration, with a level below 0.2 nanograms per milliliter indicating severe depletion, and by the measurement of PIVKA-II, which is elevated when the hepatic vitamin K supply is insufficient.

3A. Hemorrhagic Disease of the Newborn

The newborn infant is the population at greatest risk for life-threatening phylloquinone deficiency. The human neonate is born with negligible hepatic vitamin K stores, because phylloquinone does not cross the placenta efficiently and the fetal liver has a low capacity for vitamin K storage. Breast milk contains very low concentrations of phylloquinone, approximately 1 to 3 micrograms per liter, an amount that is insufficient to meet the infant's requirement for coagulation factor synthesis. The result is a transient but profound vitamin K deficiency that develops in the first days and weeks of life and that can present as classic hemorrhagic disease of the newborn, with gastrointestinal, umbilical, and intracranial bleeding, or as late-onset hemorrhagic disease, which presents after the first week and is often associated with intracranial hemorrhage. The universal practice of administering a single intramuscular dose of 1 milligram of phylloquinone immediately after birth was introduced in the 1960s and has virtually eliminated this condition in countries where it is standard practice. The intramuscular route is superior to the oral route and should be the default recommendation. The historical concern, raised in the 1990s, that intramuscular vitamin K might be associated with an increased risk of childhood leukemia has been exhaustively investigated and refuted by multiple large, well-designed epidemiological studies. The safety of the neonatal intramuscular dose is established.

3B. Acquired Deficiency in Adults

Acquired phylloquinone deficiency in adults is uncommon in the absence of a specific precipitating condition. The most common cause is the combination of poor dietary intake and the use of broad-spectrum antibiotics, which suppress the gut microbiome that synthesizes a small but potentially significant amount of menaquinones. Patients in the intensive care unit who are receiving nothing by mouth and are on broad-spectrum antibiotics can develop a prolonged INR within 7 to 10 days if parenteral vitamin K is not provided. Fat malabsorption syndromes, including celiac disease, cystic fibrosis, pancreatic insufficiency, and biliary obstruction, impair the absorption of phylloquinone and can lead to a clinically significant deficiency. Chronic liver disease, including cirrhosis, reduces the hepatic storage of phylloquinone and impairs the synthesis of the coagulation factors, and these patients often have a prolonged INR that is multifactorial in origin but that has a correctable phylloquinone deficiency component.

3C. Warfarin-Induced Functional Deficiency

Warfarin and related coumarin anticoagulants produce a pharmacological, functional vitamin K deficiency by inhibiting VKORC1 and depleting the hepatic pool of reduced phylloquinone. This is a therapeutic effect, not a nutritional deficiency, but its management requires a detailed understanding of phylloquinone pharmacology. The administration of phylloquinone is the specific antidote to warfarin, and the dose required to reverse the anticoagulant effect depends on the urgency of the clinical situation. For life-threatening bleeding, intravenous phylloquinone at 5 to 10 milligrams, in combination with prothrombin complex concentrate to immediately replace the deficient clotting factors, is the standard of care. For the asymptomatic patient with a supratherapeutic INR who is not bleeding, a low oral dose of phylloquinone, typically 1 to 5 milligrams, can partially reverse the anticoagulant effect and bring the INR back into the target range without precipitating warfarin resistance. The management of the warfarin-phylloquinone interaction is a clinical skill that is central to the practice of anticoagulation management.

The dietary intake of phylloquinone antagonizes warfarin. A patient on a stable warfarin dose who consumes a large quantity of green leafy vegetables, or who initiates a phylloquinone supplement, will experience a reduction in the INR as the increased phylloquinone supply drives the residual, uninhibited VKORC1 to generate more reduced vitamin K and to carboxylate a larger fraction of the clotting factor pool. The clinical management of this interaction is the principle of consistency. A stable, moderate intake of dietary phylloquinone, on the order of 70 to 150 micrograms per day, allows the warfarin dose to be titrated to the target INR. Wide fluctuations in phylloquinone intake destabilize the INR and require frequent monitoring and dose adjustment.

---

Part 4. The Evidence Mapped by Clinical Context

The evidence for phylloquinone is most robust in the domain of coagulation, where its efficacy is immediate, measurable by the INR, and supported by decades of clinical experience. The evidence for its role in bone and vascular health is weaker than that for MK-7, a reflection of its pharmacokinetic limitations rather than a failure of its biochemical mechanism.

4.1. Neonatal Vitamin K Prophylaxis: The Standard of Care

The intramuscular administration of 1 mg of phylloquinone at birth is one of the most effective preventive interventions in pediatrics. It reduces the incidence of classic and late vitamin K deficiency bleeding to approximately 1 in 100,000 births, compared to an incidence of 0.25 to 1.7 percent in unprotected infants. The alternative oral regimens, such as 2 mg of oral phylloquinone at birth, repeated at 1 week and 4 to 6 weeks, are less effective and are associated with a higher incidence of late bleeding, particularly in exclusively breastfed infants and in those with undiagnosed cholestatic liver disease. The intramuscular route is the standard of care recommended by the American Academy of Pediatrics and the World Health Organization.

4.2. Warfarin Reversal and Anticoagulation Management

Intravenous phylloquinone is the specific antidote for warfarin and superwarfarin anticoagulation. The dose and the route are determined by the INR and the clinical scenario. For a supratherapeutic INR (greater than 10) without bleeding, oral phylloquinone at a dose of 2.5 to 5 mg is recommended, with the INR rechecked at 24 hours. For major bleeding or the need for urgent surgery, intravenous phylloquinone at 1 to 10 mg, infused slowly over 20 to 30 minutes to minimize the risk of anaphylactoid reaction, is administered in combination with a prothrombin complex concentrate or fresh frozen plasma. The prothrombin complex concentrate provides the immediate replacement of the vitamin K-dependent clotting factors. The phylloquinone supports the hepatic synthesis of new, carboxylated factors over the subsequent 6 to 24 hours. The intravenous route is preferred over the subcutaneous route for urgent reversal because of the more predictable absorption and the faster onset of action. The intramuscular route is avoided in the anticoagulated patient because of the risk of hematoma formation.

For the chronic management of warfarin-induced INR instability, low-dose oral phylloquinone at 100 to 200 micrograms per day has been studied as a strategy to reduce INR variability. A 2010 meta-analysis of randomized trials found that daily supplementation with 150 to 200 micrograms of phylloquinone reduced the standard deviation of the INR and increased the time in the therapeutic range compared to placebo, particularly in patients with a low habitual dietary vitamin K intake and a highly variable INR. The mechanism is the stabilization of the hepatic phylloquinone pool, reducing the sensitivity of the INR to the day-to-day fluctuations in dietary vitamin K intake. This strategy is not universally adopted but is a reasonable consideration for the patient on warfarin with unexplained INR lability and a low dietary phylloquinone intake.

4.3. Bone Health: The Observational-Interventional Discrepancy

The epidemiological evidence linking low phylloquinone intake to an increased risk of hip fracture is consistent across multiple cohort studies. The randomized trials of phylloquinone supplementation for bone health, however, have not demonstrated a consistent benefit. The interpretation of this discrepancy is that phylloquinone, while essential for the carboxylation of osteocalcin, is not the limiting factor for bone health in most populations, and its short half-life limits its capacity to sustain the carboxylation of osteocalcin over a 24-hour period. Phylloquinone should not be recommended as a monotherapy for the prevention or treatment of osteoporosis. The menaquinones, particularly MK-7 and the pharmacological dose of MK-4, are the vitamin K forms with the stronger evidence base for bone health.

4.4. Cardiovascular Disease: The Phylloquinone-Menaquinone Divide

The Rotterdam Study and other prospective cohort studies have consistently found that dietary phylloquinone intake is not associated with a reduced risk of coronary heart disease or aortic calcification, in contrast to the strong protective associations observed for the menaquinones. This finding is consistent with the pharmacokinetic profile of phylloquinone, which is rapidly cleared by the liver and does not reach the arterial wall in sufficient concentrations to sustain the carboxylation of MGP over time. Phylloquinone is not the appropriate form of vitamin K for the prevention of vascular calcification. The menaquinones, particularly MK-7, are the forms that have the pharmacokinetic properties required for this indication.

---

Part 5. A Clinical Dosing Compendium: The Coagulation Vitamin and the Circulating Precursor

Phylloquinone dosing is defined by the clinical objective: the prevention of deficiency in the neonate, the correction of the coagulopathy in the deficient adult, the reversal of warfarin anticoagulation, the management of INR instability, and the provision of substrate for the UBIAD1-mediated tissue MK-4 synthesis.

5.1. Evidence-Based Protocols: Dosing Supported by Clinical Trial and Standard-of-Care Data

Neonatal Vitamin K Prophylaxis. The target is the prevention of classic and late vitamin K deficiency bleeding. The evidence-based protocol is 1 mg of phylloquinone (as Konakion or AquaMEPHYTON), administered as a single intramuscular injection into the vastus lateralis muscle within 6 hours of birth. For preterm infants weighing less than 1,500 grams, the dose is reduced to 0.3 to 0.5 mg intramuscularly to minimize the risk of a large intramuscular depot in a small muscle mass. The intramuscular route is superior to the oral route and should be the default recommendation. Parents who refuse intramuscular vitamin K should be counseled about the risk of late vitamin K deficiency bleeding, including intracranial hemorrhage, and offered the oral regimen of 2 mg at birth, repeated at 1 week and 4 to 6 weeks, with the understanding that this regimen is less protective and requires strict adherence.

Correction of Vitamin K Deficiency in the Adult. The target is the normalization of the INR and the repletion of the hepatic phylloquinone pool in a patient with a coagulopathy due to malnutrition, malabsorption, antibiotic therapy, or biliary obstruction. The protocol is 10 mg of phylloquinone, administered as a single oral dose or as a single intravenous dose if the oral route is unreliable. The INR should be rechecked at 12 to 24 hours. A failure of the INR to normalize suggests liver disease, consumptive coagulopathy, or the presence of a vitamin K antagonist such as warfarin or a superwarfarin rodenticide. Chronic malabsorptive conditions, such as cystic fibrosis or short bowel syndrome, may require ongoing, intermittent phylloquinone supplementation at 5 to 10 mg orally once or twice per week, guided by the INR and the plasma PIVKA-II level.

Warfarin Reversal for Major Bleeding or Urgent Surgery. The target is the rapid correction of the INR to less than 1.5 to allow surgical hemostasis or to control life-threatening bleeding. The protocol is 5 to 10 mg of phylloquinone, administered by slow intravenous infusion (over 20 to 30 minutes to minimize the risk of anaphylactoid reaction), combined with a 4-factor prothrombin complex concentrate at a dose of 25 to 50 IU per kilogram, or fresh frozen plasma at a dose of 15 to 30 mL per kilogram if prothrombin complex concentrate is unavailable. The INR should be checked at 15 to 30 minutes after the completion of the infusion. A second dose of phylloquinone may be administered at 12 to 24 hours if the INR remains elevated.

Management of Supratherapeutic INR Without Bleeding. The target is the reduction of an elevated INR (greater than 4.5) to the therapeutic range without precipitating a thromboembolic event. The protocol is oral phylloquinone at a dose of 2.5 to 5 mg for an INR between 4.5 and 10, with the INR rechecked at 24 hours. For an INR greater than 10, the oral dose is 5 to 10 mg. The warfarin is withheld for one or two doses and resumed at a reduced dose when the INR is in the therapeutic range. Subcutaneous phylloquinone is not recommended because of its erratic and unpredictable absorption.

INR Stabilization in the Warfarin-Treated Patient with Labile Control. The target is the reduction of INR variability and the increase in the time in the therapeutic range. The protocol is 100 to 200 micrograms of oral phylloquinone per day, taken as a single tablet, with the warfarin dose adjusted to maintain the target INR. The INR should be checked within 1 week of initiating the supplement, and the warfarin dose reduced if necessary. The supplementation should be continued long-term if it is associated with an improvement in the time in the therapeutic range. The patient should be counseled about the importance of the consistency of their total daily vitamin K intake, including the supplement and the dietary sources.

Nutritional Maintenance in Adults. The target is the provision of adequate phylloquinone for the hepatic coagulation system and for the circulating precursor pool that supports tissue MK-4 synthesis. The adequate intake for phylloquinone is 120 micrograms per day for men and 90 micrograms per day for women. A diet that includes one to two servings of green leafy vegetables per day, consumed with a source of dietary fat, is sufficient to meet this requirement for most individuals. Supplementation with phylloquinone is not necessary for the general population with a normal dietary intake.

5.2. Theoretical and Postulated Dosing Frameworks for Future Investigation

High-Dose Phylloquinone for Osteoporosis: A Test of the Pharmacokinetic Hypothesis. Rationale: the failure of 500 to 1,000 micrograms per day of phylloquinone to improve bone mineral density may reflect the pharmacokinetic limitation of its short half-life, not a lack of biological activity. Postulate: a randomized trial of phylloquinone at 5 mg per day (5,000 micrograms), a dose that saturates the hepatic extraction system and maintains a sustained plasma phylloquinone concentration, for 3 years in postmenopausal women with osteoporosis, with the primary endpoint being the change in lumbar spine bone mineral density and the secondary endpoint being the incidence of vertebral fractures. The hypothesis is that a sustained, supraphysiological plasma phylloquinone concentration can fully carboxylate osteocalcin and support bone mineralization to a degree comparable to that of the menaquinones. The safety of 5 mg per day of phylloquinone, with regard to the risk of a hypercoagulable state, requires careful monitoring of the coagulation parameters and the markers of thrombin generation.

Phylloquinone for the Prevention of Arterial Calcification in Warfarin-Treated Patients. Rationale: warfarin inhibits the carboxylation of MGP and accelerates arterial calcification. The supplementation of phylloquinone at a dose that partially reverses the hepatic warfarin effect while supporting the extrahepatic carboxylation of MGP could reduce the calcification burden in patients who require long-term warfarin therapy. Postulate: a randomized trial of phylloquinone at 200 micrograms per day, a dose that stabilizes the INR in warfarin-treated patients, for 3 years, with the primary endpoint being the change in the coronary artery calcium score and the secondary endpoint being the change in the plasma dp-ucMGP concentration. The hypothesis is that a low, consistent dose of phylloquinone can partially reverse the warfarin-induced inhibition of MGP carboxylation without destabilizing the anticoagulant effect.

Maternal Phylloquinone Supplementation to Enrich Breast Milk. Rationale: human breast milk is a poor source of phylloquinone, and the exclusively breastfed infant is dependent on the neonatal prophylactic dose for the first months of life. Postulate: a randomized trial of maternal phylloquinone supplementation at 5 mg per day during lactation, with the primary endpoint being the phylloquinone concentration in the breast milk and the secondary endpoint being the plasma phylloquinone and PIVKA-II concentrations in the exclusively breastfed infant. The hypothesis is that high-dose maternal supplementation can increase the breast milk phylloquinone concentration to a level that provides ongoing protection against vitamin K deficiency bleeding beyond the neonatal period.

Phylloquinone and the Brain: The UBIAD1-MK-4 Conversion Hypothesis. Rationale: the brain expresses UBIAD1 and converts phylloquinone to MK-4. The hypothesis that phylloquinone is a circulating pro-vitamin for the cerebral synthesis of MK-4, and that the dietary intake of phylloquinone supports brain Gas6 function and myelin maintenance, has not been tested in an interventional trial. Postulate: a randomized trial of phylloquinone at 1,000 micrograms per day for 2 years in older adults with mild cognitive impairment, with the primary endpoint being the change in a cognitive composite score and the secondary endpoint being the change in the cerebrospinal fluid MK-4 concentration. The hypothesis is that phylloquinone supplementation will increase the brain MK-4 concentration and support the Gas6-TAM signaling pathway that maintains white matter integrity. This trial would require cerebrospinal fluid sampling and is logistically demanding, but it would address the question of whether phylloquinone has a neuroprotective role independent of its hepatic function.

The Quantitative Contribution of the Phylloquinone-to-MK-4 Conversion Pathway. The UBIAD1 enzyme is expressed in specific tissues, and the conversion of phylloquinone to MK-4 has been demonstrated in animal models. The extent to which this pathway contributes to the tissue MK-4 pool in humans, and whether it can be upregulated by increased phylloquinone intake, is not known. A study that administers isotopically labeled phylloquinone to human volunteers and measures the incorporation of the label into tissue MK-4 would provide the definitive answer and would inform the dietary recommendations for vitamin K intake.

Can High-Dose Phylloquinone Supplementation Compensate for the Absence of Dietary Menaquinones? The short half-life of phylloquinone limits its capacity to sustain extrahepatic Gla protein carboxylation over a 24-hour period. A theoretical strategy to overcome this limitation is the use of a high, sustained-release dose of phylloquinone, or a regimen of multiple daily doses, to maintain a continuous supply to the extrahepatic tissues. The efficacy of such a regimen for the carboxylation of MGP and the prevention of arterial calcification, compared to MK-7, has not been tested. The investigation of this question is relevant to the design of vitamin K supplementation strategies for populations that do not consume fermented foods and have a low dietary intake of menaquinones.

5.3. Universal Principles Governing Phylloquinone Dosing

The Intravenous Route is Reserved for Emergencies. Intravenous phylloquinone is the most rapid and reliable method for correcting the INR in the setting of major bleeding or the need for urgent surgery. It should be administered by slow infusion to minimize the risk of an anaphylactoid reaction, which is a rare but well-documented complication that is attributed to the polyethoxylated castor oil vehicle in certain phylloquinone formulations, not to the phylloquinone molecule itself. The oral route is preferred for all non-emergency indications, including the correction of vitamin K deficiency in the stable patient and the management of a supratherapeutic INR without bleeding.

Absorption is Fat-Dependent and Variable. Phylloquinone is a lipophilic molecule that requires the presence of dietary fat and an intact enterohepatic circulation for its optimal absorption. A patient with cholestasis, pancreatic insufficiency, or a severe intestinal mucosal disease will not absorb oral phylloquinone reliably. The parenteral route, either intravenous or intramuscular, is required for these patients when a predictable increase in the plasma and hepatic phylloquinone concentration is the therapeutic goal.

Phylloquinone is Not Menaquinone-7. The clinical literature on vitamin K and chronic disease (bone health, vascular calcification, cognitive function) is dominated by the menaquinones, particularly MK-7. The extrapolation of these data to phylloquinone is not justified by the pharmacokinetic differences between the two forms. Phylloquinone should be prescribed for the hepatic indication (coagulation) and for the warfarin interaction. MK-7 is the agent of choice for the long-term nutritional support of bone and vascular health. The two forms are complementary, not competitive, and the optimal vitamin K status for the human organism requires the adequacy of both: phylloquinone for the liver and for the circulating precursor pool, and the menaquinones for the extrahepatic tissues that cannot be adequately supplied by phylloquinone alone.

The INR is the Pharmacodynamic Monitor for Hepatic Phylloquinone Status. The INR is a sensitive, specific, and widely available biomarker of the hepatic vitamin K-dependent coagulation factor carboxylation. It is the appropriate monitoring tool for the management of phylloquinone therapy in the context of deficiency, warfarin reversal, and INR stabilization. The plasma PIVKA-II and the plasma phylloquinone concentration provide additional information in research settings and in the evaluation of the patient with an unexplained coagulopathy, but they are not required for the routine clinical management of phylloquinone dosing.

The UBIAD1 Conversion Pathway is a Nutritional Safety Net. The capacity of extrahepatic tissues to convert phylloquinone to MK-4 provides a mechanism by which dietary phylloquinone can support tissue Gla protein function even in the absence of dietary menaquinones. This pathway is likely sufficient to prevent the most severe consequences of extrahepatic vitamin K deficiency but may not be sufficient to achieve the optimal carboxylation of MGP and osteocalcin, which requires the sustained supply of the long-chain menaquinones. The clinical approach to vitamin K supplementation must therefore distinguish between the hepatic and the extrahepatic indications, recognizing that the two forms of vitamin K serve distinct and complementary functions in human biology.

---

Part 6. The Unresolved Frontier

The UBIAD1-Mediated Conversion and Its Regulation. The enzyme that converts phylloquinone to MK-4, UBIAD1, is the same enzyme that is mutated in Schnyder corneal dystrophy, a disorder of corneal cholesterol and phylloquinone accumulation. The regulation of UBIAD1 by the cellular sterol and isoprenoid status is incompletely understood. The observation that statins, which inhibit the mevalonate pathway and deplete the geranylgeranyl pyrophosphate pool, might reduce the conversion of phylloquinone to MK-4 in peripheral tissues, and thereby impair the extrahepatic Gla protein carboxylation, is a hypothesis of potential clinical significance. The test of this hypothesis would require the measurement of the tissue MK-4 concentration and the plasma dp-ucMGP in patients on chronic statin therapy, with and without phylloquinone or MK-4 supplementation.

Phylloquinone and the Developing Brain. The neonatal brain undergoes a period of rapid myelination and synaptogenesis in the first two years of life, processes that involve the Gas6-TAM signaling pathway. The neonatal brain expresses UBIAD1 and synthesizes MK-4 from phylloquinone. The question of whether the intramuscular phylloquinone administered at birth contributes to the brain's MK-4 pool and supports the developmental myelination program, or whether the dose is entirely consumed by the liver for coagulation factor synthesis, is unanswered. The long-term neurodevelopmental outcomes of infants who received intramuscular versus oral vitamin K prophylaxis, or who received different doses of phylloquinone, have not been systematically studied.

Phylloquinone as a Biofortification Target. The phylloquinone content of plant foods is variable and is determined by the chloroplast density and the activity of the photosynthetic apparatus. The biofortification of staple crops, such as rice or wheat, with increased phylloquinone content, or the enhancement of the phylloquinone content of leafy vegetables through the manipulation of the chloroplast development pathways, are strategies that could improve the vitamin K status of populations that depend on plant-based diets. The conversion of the additional phylloquinone to MK-4 in the tissues of the consumer, and the effect of this conversion on the extrahepatic Gla protein carboxylation, would be a relevant endpoint for such programs.

The Interaction of Phylloquinone with Vitamin D and Calcium. Vitamin D stimulates the synthesis of MGP and osteocalcin. Vitamin K carboxylates them. Calcium is the mineral they chaperone. The three nutrients form a functional triad for calcium distribution. The combination of vitamin D and calcium without vitamin K may, in theory, promote the carboxylation of the hepatic clotting factors while leaving the extrahepatic Gla proteins undercarboxylated, a state that could increase the risk of arterial calcification if the calcium intake is high. This hypothesis, while mechanistically plausible, has not been tested in a randomized trial. The clinical approach that is consistent with the biology is to ensure the adequacy of all three nutrients, with vitamin D and calcium dosed to achieve normal serum 25-hydroxyvitamin D and adequate total calcium intake, and vitamin K, in the form appropriate to the therapeutic goal, dosed to normalize the relevant biomarker (INR for hepatic status, dp-ucMGP for extrahepatic status).

---

Part 7. Synthesis for an Evidence-Based Approach

Phylloquinone is the original vitamin K, the plant-derived naphthoquinone that has been known to medicine for nearly a century as the coagulation vitamin. Its hepatic function is essential and non-redundant. The gamma-carboxylation of the clotting factors, the prevention of hemorrhagic disease of the newborn, and the reversal of warfarin anticoagulation are clinical indications that are specific to phylloquinone and that cannot be adequately addressed by the menaquinones alone. The liver is a phylloquinone-avid organ, and the short half-life of phylloquinone in the plasma is a consequence of its rapid and efficient hepatic extraction. This pharmacokinetic profile makes phylloquinone an ideal hepatic vitamin and a suboptimal extrahepatic vitamin.

The recognition that phylloquinone is also the circulating precursor for tissue-specific MK-4 synthesis, through the UBIAD1 enzyme expressed in the brain, the pancreas, the testis, and the arterial wall, expands the biological significance of this molecule beyond the coagulation cascade. Dietary phylloquinone is the substrate for a network of local MK-4 production that supports the carboxylation of Gas6 in the nervous system and MGP in the vasculature. This conversion pathway provides a mechanistic link between phylloquinone intake and the non-coagulation functions of vitamin K, and it suggests that a dietary deficiency of phylloquinone may have consequences that extend beyond the prolongation of the prothrombin time.

The clinical approach to vitamin K supplementation must distinguish between the hepatic and the extrahepatic indications. Phylloquinone is the agent of choice for the prophylaxis of neonatal hemorrhage, the treatment of acquired vitamin K deficiency, and the reversal of warfarin. MK-7 is the agent of choice for the long-term nutritional support of bone and vascular health. The two forms are complementary, not competitive, and the optimal vitamin K status for the human organism requires the adequacy of both: phylloquinone for the liver and for the circulating precursor pool, and the menaquinones for the extrahepatic tissues that cannot be adequately supplied by phylloquinone alone. The clinician who understands this distinction and who applies it to the individual patient, the neonate, the anticoagulated, the osteoporotic, and the aging adult with arterial stiffness, is practicing at the intersection of the coagulation biology of the mid-twentieth century and the calcification biology of the twenty-first, a position that is both scientifically grounded and clinically actionable.

The frontier of phylloquinone biology is the UBIAD1-mediated conversion to MK-4, a pathway that links the dietary intake of the plant vitamin to the tissue concentrations of the animal menaquinone. The regulation of this conversion, its response to pharmacological inhibitors of the mevalonate pathway, its quantitative contribution to the tissue MK-4 pool in humans, and its significance for the neurodevelopment of the infant and the cognitive function of the aging adult are open questions that will define the next chapter of phylloquinone research. The molecule that was discovered as the anti-hemorrhagic factor in the 1930s continues to reveal new dimensions of its biology, but its primary clinical identity remains unchanged: phylloquinone is the vitamin that stops the bleeding, and its use for that purpose is among the most firmly established interventions in medicine.